Nexavar, or sorafenib, is made by Bayer and Onyx
Pharmaceuticals, and is already approved to treat advanced kidney
cancer and liver cancer that cannot be surgically removed.
Bayer is testing the drug, taken orally, as an additional treatment
for liver cancer patients who had no detectable disease after
surgery. It said on Tuesday that the trial did not meet its main
goal of improving recurrence-free survival.
"We are disappointed that the trial did not meet its primary
endpoint," said Joerg Moeller, member of the Bayer HealthCare
Executive Committee. "However, we remain committed to exploring the
full potential of sorafenib in all stages of liver cancer."
Bayer shares were down 0.3 percent in early trade, underperforming a
0.2 percent rise for German blue chips.
Liver cancer is the sixth-most common cancer in the world with more
than 780,000 cases diagnosed each year, Bayer said.
(Reporting by Victoria Bryan; editing by Christoph Steitz and Mark Potter)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.